(Paywall) Crain’s New York Business spotlighted how both the House and Senate have advanced the reauthorization of the SBIR and STTR grant programs following a six month lapse.

NewYorkBIO CEO Jennifer Hawks Bland described the pause as a “double whammy” for early-stage companies facing both frozen access to capital and barred from applying for future funding.

With the legislation now sitting on the President’s desk, this renewal marks a critical step toward stabilizing early-stage funding and strengthening New York’s biotech pipeline.